摘要
目的:观察培美曲塞二钠(pemetrexed disodium,PEM)联合卡铂(carboplatin,CBP)在晚期老年非小细胞肺癌(NSCLC)中的临床疗效及不良反应。方法:102例晚期老年(≥60岁)非小细胞肺癌患者分成培美曲塞二钠组(A组)和吉西他滨组(B组),A组:培美曲塞二钠/卡铂(51例),B组:吉西他滨(GEM)/卡铂(51例)。PEM:500mg·m-2,静脉滴注,d1;CBP300mg·m-2,静脉滴注,d1,21d为1个周期。GEM1000mg·m-2,d1,8,CBP300mg·m-2,d1,21d为1个周期。结果:102例患者的症状均有不同程度的改善。A组和B组有效率为41.2%、37.3%,2组间无显著性差异(P>0.05)。不良反应方面,B组对血象的影响、恶心呕吐症状及脱发的发生率明显高于A组(P<0.05)。结论:PEM/CBP与GEM/CBP对晚期老年非小细胞肺癌的近期临床疗效相近,但PEM组耐受性及不良反应低于GEM组,培美曲塞二钠联合卡铂方案可作为治疗晚期老年非小细胞肺癌有效的化疗方案。
OBJECTIVE：To observe the clinical efficacy and toxicities of pemetrexed disodium（PEM） combined with Carboplatin（CBP） for elderly patients with advanced non-small-cell lung carcinoma（NSCLC）.METHODS：A total of 102 NSCLC patients aged over 60 years were randomly assigned to receive either PEM 500 mg·m-2 iv gtt on day 1 plus CBP500 mg·m-2 iv gtt on day 1（Group A,n = 51） or Gemcitabine 1 000 mg·m-2 on days 1 and 8 plus CBP 300 mg·m-2 on day 1（Group B,n = 51）,with 21 days defined as one treatment cycle.RESULTS：All the 102 cases showed improvement of different degree in clinical symptoms.There were no significant differences between the two groups in overall response rate（41.2% in Group A vs.37.3% in Group B,P 〉 0.05）.Regarding toxicities,the incidences of leucopenia/thrombocytopenia,nausea and vomiting and alopecia in B group were significantly higher than in Group A（P 〈 0.05）.CONCLUSION：PEM/CBP and GEM/CBP showed similar short-term efficacy for aged NSCLC patients,however,the tolerability and toxicities in PEM group were lower than in GEM group,thus,PEM combined with CBP is an effective chemotherapeutic regimen for advanced NSCLC in aged patients
出处
《中国医院用药评价与分析》
2010年第11期1018-1020,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
培美曲塞二钠
非小细胞肺癌
老年
化疗
Pemetrexed disodium； Non-small-cell lung carcinoma（NSCLC）； Elderly； Chemotherapy；
